NCT05621239View on ClinicalTrials.gov

A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People

CompletedOBSERVATIONAL
Enrollment

260

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

April 3, 2023

Study Completion Date

April 3, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

BNT162b2

BNT162b2 half dose and full dose

Trial Locations (1)

Unknown

Pfizer, Jakarta

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05621239 - A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People | Biotech Hunter | Biotech Hunter